Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Iterum Therapeutics' NDA resubmission for oral sulopenem to treat uncomplicated urinary tract infections in adult women is accepted by the FDA, with a PDUFA action date of October 25, 2024.
Highlighted Terms
Related News
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Iterum Therapeutics' NDA resubmission for oral sulopenem to treat uncomplicated urinary tract infections in adult women is accepted by the FDA, with a PDUFA action date of October 25, 2024.